Travoprot compared with latanoprot and timolol in patient with open-angle glaucoma or ocular hypertenion

PURPOE: Thi tudy evaluated the afety and intraocular preure–lowering efficacy of two concentration of travoprot (0.0015% and 0.004%) compared with latanoprot 0.005% and timolol 0.5% in patient with open-angle glaucoma or ocular hypertenion. METHOD: Eight hundred one patient with open-angle glaucoma or ocular hypertenion were randomly aigned to travoprot 0.0015%, travoprot 0.004%, latanoprot 0.005%, or timolol 0.5%. The efficacy and afety of travoprot (0.0015% and 0.004%) daily wa compared with latanoprot daily and timolol twice daily for a period of 12 month. REULT: Travoprot wa equal or uperior to latanoprot and uperior to timolol with mean intraocular preure over viit and time of day ranging from 17.9 to 19.1 mm Hg (travoprot 0.0015%), 17.7 to 19.1 mm Hg (travoprot 0.004%), 18.5 to 19.2 mm Hg (latanoprot), and 19.4 to 20.3 mm Hg (timolol). For all viit pooled, the mean intraocular preure at 4 for travoprot wa 0.7 mm Hg (0.0015%, P = .0502) and 0.8 mm Hg (0.004%, P = .0191) lower than for latanoprot. Travoprot 0.004% wa more effective than latanoprot and timolol in reducing intraocular preure in black patient by up to 2.4 mm Hg (veru latanoprot) and 4.6 mm Hg (veru timolol). Baed on a criterion of 30% or greater intraocular preure reduction from diurnal baeline or intraocular preure 17 mm Hg or le, travoprot 0.0015% and 0.004% had an overall repone to treatment of 49.3% and 54.7%, repectively, compared with 49.6% for latanoprot and 39.0% for timolol. Iri pigmentation change wa oberved in 10 of 201 of patient (5.0%) receiving travoprot 0.0015%, ix of 196 of patient (3.1%) receiving travoprot 0.004%, 10 of 194 of patient (5.2%) receiving latanoprot, and none of the patient receiving timolol (0 of 196). The average ocular hyperemia core wa le than 1 on a cale of 0 to 3, indicating that on average patient experienced between none/trace and mild for all treatment group. There were no eriou, unexpected, related advere event reported for any therapy. CONCLUION: Travoprot (0.0015% and 0.004%), a highly elective, potent protaglandin F (FP) receptor agonit, i equal or uperior to latanoprot and uperior to timolol in lowering intraocular preure in patient with open-angle glaucoma or ocular hypertenion. In addition, travoprot 0.004% i ignificantly better than either latanoprot or timolol in lowering intraocular preure in black patient. Travoprot i afe and generally well tolerated in the tudied patient population.